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Objective: To identify and characterize patient-centered outcomes (PCOs) relating to multiparametric MRI (mpMRI) and MRI-guided
biopsy as diagnostic tests for possible prostate cancer.
Methods: Medline via OVID, EMBASE, PsycInfo, and the Cochrane Central register of Controlled Trials (CENTRAL) were searched
for relevant articles. Hand searching of reference lists and snowballing techniques were performed. Studies of mpMRI and MRI-guided
biopsy that measured any PCO were included. There were no restrictions placed on year of publication, language, or country for study
inclusion. All database search hits were screened independently by two reviewers, and data were extracted using a standardized form.
Results: Overall, 2,762 database search hits were screened based on title and abstract. Of these, 222 full-text articles were assessed, and
10 studies met the inclusion criteria. There were 2,192 participants featured in the included studies, all of which were conducted in
high-income countries. Nineteen different PCOs were measured, with a median of four PCOs per study (range 1-11). Urethral bleeding,
pain, and urinary tract infection were the most common outcomes measured. In the four studies that compared mpMRI or MRI-guided
biopsy to transrectal ultrasound biopsy, most adverse outcomes occurred less frequently in MRI-related tests. These four studies were
assessed as having a low risk of bias.
Discussion: PCOs measured in studies of mpMRI or MRI-guided biopsy thus far have mostly been physical outcomes, with some
evidence that MRI tests are associated with less frequent adverse outcomes compared with transrectal ultrasound biopsy. There was very
little evidence for the effect of mpMRI and MRI-guided biopsy on emotional, cognitive, social, or behavioral outcomes.
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INTRODUCTION
The current diagnostic tests for prostate cancer have
important limitations, which can impact patients. Pros-
tate biopsy via the transrectal (TRUS) or transperineal
route under ultrasound guidance carry a risk of adverse
effects [1], and both have a significant false-negative rate
leading to potential underdiagnosis [2]. In recent years
there has been increasing interest in the potential utility of
multiparametric MRI (mpMRI) as a new diagnostic test
for prostate cancer. mpMRI could avoid the need for up
to 28% of men to undergo a prostate biopsy for possible
prostate cancer if used as a prebiopsy triage test [3].
MRI-guided biopsy has been shown to increase the diag-
nostic accuracy for clinically significant prostate cancer
and reduce the numbers of patients diagnosed with
clinically insignificant prostate cancer [4,5].
Mortality benefits, diagnostic accuracy, and adverse
effects are all important clinical outcomes of diagnostic
tests, but they are not the only elements that need to be
considered. The Agency for Healthcare Research and
Quality Effective Healthcare Program White Paper series
on diagnostic test evaluation proposed that, in addition to
the clinical outcome, a medical test can have emotional,
social, cognitive, and behavioral outcomes for patients.
These outcomes can be positive or negative, and they are
not restricted to the medical test itself, but the entire
diagnostic pathway [6].
Outcomes that are considered to have most impor-
tance or meaning to patients are often referred to as
patient-centered outcomes (PCOs), although a precise
definition of PCOs has not yet been reached [7]. The
Patient-Centered Outcomes Research Institute
(PCORI) has been established to support and conduct
research into the comparative effectiveness of health care
interventions to inform patient and clinical decision
making. PCOs have three domains [8]:
1. Assessment of harms and benefits to inform decision
making, highlighting comparisons and outcomes that
matter to people
2. A focus on outcomes that people notice and care about
3. The incorporation of a wide variety of settings and
diversity of participants
Among the PCORI portfolio, there is some ongoing
work exploring the most important outcomes for patients
from diagnostic tests [9].
This systematic review aims to summarize and
compare the current evidence relating to PCOs for
mpMRI or MRI-guided biopsy as a diagnostic test in
men suspected of having prostate cancer.2
METHODS
The protocol for this systematic review has been pub-
lished on PROSPERO [10].
In summary, databases including Medline via OVID,
EMBASE, PsycInfo, and the Cochrane Central register of
Controlled Trials (CENTRAL) were selected to search for
relevant articles. The Cochrane Collaboration recommends
combining the test(s) of interest with the specific condition
to refine searches [11]. This approach was merged with
pretested search filters developed by the Scottish
Intercollegiate Guidelines Network [12] for “diagnostic
studies” and “patient issues” to achieve balance between
the sensitivity and precision of the search strategy (see e-
only Appendix 1). Hand searching and snowballing
techniques from reference lists of systematic reviews and
key references were performed to identify potentially
relevant studies not captured by database searches.
The inclusion criteria were: (1) studies of MRI-guided
biopsy or mpMRI for possible prostate cancer diagnosis
and (2) PCOs included as an outcome measure in the
study (as primary or secondary outcomes).
There were no limits set on date of publication,
language, or study design. All database search hits were
assessed independently against the inclusion criteria by
two reviewers (S.M., V.H.). Disagreements were resolved
with a third reviewer (W.H.). Full-text articles were
reviewed, and data were extracted from full-text studies
using a standardized form piloted in three studies and
iteratively developed to capture all possible PCOs. Study
quality for randomized controlled trials (RCTs) was
assessed with the Cochrane Risk of Bias tool [13], and the
MINORS checklist [14] was used for nonrandomized
studies. A narrative approach was used to synthesize
findings due to significant study heterogeneity. This
manuscript was written following the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses statement [15] (see e-only Appendix 2).RESULTS
In all, 2,762 records were identified through database and
hand searching. After removal of duplicates and screening
of titles and abstracts, 222 full-text articles were assessed.
Ten publications were included in the systematic review.
A full breakdown of study selection and reasons for full-
text exclusions is in Figure 1.Study Characteristics
Seven of the included studies were performed in Euro-
pean countries, two in the United States and one inJournal of the American College of Radiology
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Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram (from Moher et al [37]).Australia. Mean ages for participants in included studies
ranged from 63 to 66 years, and the numbers of partic-
ipants ranged from 8 to 576. Studies varied widely in
terms of design, participant numbers, and outcomes
measured. Table 1 contains full details of all included
studies. Of the 10 included studies, 4 [5,16-18] were
assessed as having a low risk of bias (see Table 2).
Nineteen different outcomes were measured across the
10 included studies, measuring an average of 4.9 outcomes
per study. The number of outcomes measured in indi-
vidual studies varied from 1 to 11. Included publications
very seldom justified the selection of outcomes measured
(see Table 3 for further information on outcomes
measured).Physical Effects
Bleeding. Bleeding after investigation was the most
commonly measured outcome. Bleeding was categorizedJournal of the American College of Radiology
Health Services Research and Policy n Merriel et al n PCOS fromas urethral bleeding, rectal bleeding, hematospermia, or
hematoma. Bleeding was measured through self-report
from patients via survey or interview in all studies (one
unreported), and reporting occurred between 7 and 56
days after biopsy. The proportion of patients reporting
some type of bleeding after biopsy varied between studies
from 0% to 88.4% [6,16,17,19-22].
Pain. Pain was measured in five studies: three utilized a
10-point visual analogue scale [6,17,23], two relied on
patient self-report [16,20], and one measured the
presence of pain 4 days after biopsy [17]. Pain was
measured between 0 and 56 days postprocedure.
Kasivisvanathan et al found a mean visual analogue
scale of 1 for MRI-guided biopsy and 2 for TRUS bi-
opsy, though without performing significance testing [5].
Egbers et al found a significantly lower pain score from
patients undergoing MRI-guided biopsy compared with
TRUS biopsy (median visual analogue scale 2 versus 3,
P < .005) [17].3
mpMRI and MRI-Guided Biopsy
Table 1. Details of included studies
Author (Year)















Egbers et al (2015)
[17]











et al (2018) [5]
Multiple RCT 500 64.4 mpMRI  MRI-GB or
TRUS-GB
30 Physical, QoL
Kuru et al (2013) [21] Germany Prospective 347 65 Fusion MRI–TRUS biopsy 28 Physical
Miah et al (2018)
[20]
UK Prospective 249 63.7 mpMRI and TTPM 56 Physical, QoL
Pokorny et al (2014)
[18]




Powell et al (2014)
[23]
USA Prospective 30 Unreported mpMRI with colorectal or
prostatic coil
0 Physical
Stanley et al (2016)
[28]








99 66.01 Manual or robotic
MRI-guided TTPM
Physical
mpMRI ¼ multiparametric MRI; MRI-GB ¼ MRI-guided biopsy; QoL ¼ quality of life; RCT ¼ randomized controlled trial; TRUS ¼ transrectal
ultrasound biopsy; TRUS-GB ¼ TRUS-guided biopsy; TTPM ¼ transperineal temple prostate mapping biopsy.Infection. Urinary tract infection and urosepsis are also
important potential adverse effects from undergoing a
prostate biopsy and were measured in five publications. A
mixture of measures, including recorded fever, urine
culture, clinical notes review, and patient self-report, were
utilized to asses for signs of infection. Sepsis (0.4%-1.6%)
[6,16,19] occurred less commonly than urinary tract
infection (1%-9.2%) [6,16,21,20,24] across the
individual studies, which measured this outcome.
Urinary Retention. Four studies [6,16,20,25] assessed
whether patients went into acute urinary retention after
undergoing a prostate biopsy, measured 30 to 56 hours
after the biopsy. Consistent with most other outcomes,
this was mostly measured by patient self-report. In the
study by Miah et al [20], which used MRI-guided trans-
perineal template mapping biopsy, 22.6% (56 of 249) of
men suffered urinary retention, whereas it was much less
common in the other studies that used TRUS-guided
biopsy (1%-10%) or MRI-TRUS fusion biopsy (1.9%).
Erectile Dysfunction. Problems achieving or maintain-
ing erection after prostate biopsy are recognized as a
potential adverse effect [26]. One study measured this
using the International Index of Erectile Function [20];4
and three used self-report [5,16,27]. Follow-up time for
this outcome was also longer than for others (median 30
days, range 28-56). Erectile dysfunction occurred in be-
tween 10.8% and 26.3% of men.
Lower Urinary Tract Symptoms. Symptoms such as
waking frequently in the night to pass urine, passing
urine often, and having a poor stream are among a group
of symptoms commonly referred to as lower urinary tract
symptoms (LUTS). LUTS usually occur due to diseases
of the prostate or the bladder, though they can also occur
after prostate biopsy. Miah et al measured LUTS using
the International Prostate Symptoms Score [20], and
showed a small increase in the presence of LUTS post-
biopsy (10.93  6.77 prebiopsy versus 11.76  6.56
postbiopsy, P ¼ .024).Emotional Effects
Stanley et al was the only study to specifically measure
anxiety relating to undergoing an MRI scan and found
that there was no difference whether patients received an
intervention aimed at reducing anxiety or not. In both
the intervention and control groups, 39% of participants
reported preprocedure anxiety [28].Journal of the American College of Radiology
Volume - n Number - n Month 2019
Table 2. Study quality assessment
Author (Year) [Reference] Randomization Deviation Missing Data Measurement Selection Overall
Randomized studies*
Kasivisvanathan et al (2018) [5] Low risk Low risk Low risk Low risk Low risk Low risk

























Ahmed et al (2017)
[16]
2 2 2 2 2 0 2 2 14‡
Egbers et al (2015)
[17]
2 2 2 2 2 1 2 0 13‡
Hadaschik et al
(2011 [24])
2 1 0 2 0 0 0 0 5§
Kuru et al (2013)
[21]
2 1 1 1 1 1 0 0 7k
Miah et al (2018)
[20]
1 2 2 2 2 1 2 0 12k
Pokorny et al (2014)
[18]
2 2 2 2 1 1 2 0 12k 2 2 2 2 20‡
Stanley et al (2016)
[28]
2 1 2 1 0 1 0 0 7k 1 2 1 1 12k
Tilak et al (2015)
[22]
2 1 1 1 0 1 0 0 6§ 1 1 1 2 11k
Calc ¼ calculation; Fup ¼ follow-up; Pts ¼ patients.
*Risk of bias assessment for included randomized controlled trials [13].











































Table 3. PCOs from all included studies
PCO (Measure)










































UTI 6% 5.4% 0 (unreported) 1% 9.2%
Fever 2.2% 4.2%
Sepsis 1% 0.4% (notes review) 0
Erectile
dysfunction






Quality of life outcomes






Outcomes were measured through self-report unless otherwise stated, and were presented as proportions who reported the outcome. EQ5-D ¼ EuroQol-5 Dimensions; IIEF ¼ International Index of Erectile
Function; IPSS ¼ International Prostate Symptom Score; ISS ¼ International Prostate Symptom Score; LUTS ¼ lower urinary tract symptoms; mpMRI ¼ multiparametric MRI; PCO ¼ patient-centered

































Retention Fever UTI Urosepsis ED Incontinence QoL Vasovagal
Ahmed et al
(2017) [16]
* ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡
Egbers et al
(2015) [17]




* * * * † * † * * † * ‡
Pokorny et al
(2014) [18]
‡ * ‡ ‡ ‡ ‡ ‡ * ‡ ‡ ‡ †
ED ¼ erectile dysfunction; mpMRI ¼ multiparametric MRI; QoL ¼ quality of life; TRUS ¼ transrectal ultrasound; UTI ¼ urinary tract infection.
*Less frequent from mpMRI or MRI-guided biopsy
†Less frequent from TRUS-guided biopsy.
‡Patient-centered outcome not measuredQuality of Life
Kasivisvanathan et al assessed patients undergoing
prostate biopsy for changes in quality of life using the
EuroQol-5 Dimensions and demonstrated a nonsignifi-
cant difference after TRUS-guided biopsy (0.27; 95%
confidence interval [CI] 1.88 to 1.33) compared with
MRI-guided biopsy (0.0004; 95% CI 0.028 to
0.020) [5]. Miah et al measured quality of life using a
subsection of the International Prostate Symptoms
Score involving one question with a 7-point Likert
scale (7 being low), showing a mean score of 1.76
(1.39) postbiopsy [20].mpMRI/MRI Guided Biopsy Versus TRUS-Guided
Biopsy
Four studies included mpMRI or MRI-guided biopsy and
TRUS-guided biopsy. Kasivisvanathan et al randomized
patients to mpMRI, with MRI-guided biopsy if a lesion
was detected or TRUS-guided biopsy [5] for a
multicenter, randomized, noninferiority trial in 11
countries. Two studies (one in the UK and one in
Australia) compared mpMRI with subsequent MRI-
guided biopsy to TRUS-guided biopsy in the same pa-
tients in prospective cohort studies [16,18] and one in a
cross-sectional study in Germany [17]. Table 4 shows a
comparison of the outcomes measured between MRI-
and TRUS-guided biopsy.DISCUSSION
Key Findings
This systematic review of PCOs associated with mpMRI
and MRI-guided biopsy for prostate cancer found wideJournal of the American College of Radiology
Health Services Research and Policy n Merriel et al n PCOS fromvariation in study quality, PCOs measured, tools used for
measurement, follow-up of patients, and outcomes. In
the four studies that compared mpMRI and subsequent
MRI-guided biopsy with TRUS-guided biopsy, most
adverse PCOs were less frequent with MRI testing. Pain
and bleeding were the most commonly measured PCOs.
In contrast, there were no published studies measuring
any cognitive, social, or behavioral outcomes of mpMRI
or MRI-guided biopsy. Meta-analysis was not possible
due to significant heterogeneity.Comparison With Existing Literature
This is the first systematic review of PCOs associated with
mpMRI and MRI-guided biopsy for prostate cancer, as
far as the authors are aware. Glaser et al performed a
literature review of the effects of prostate biopsy on uri-
nary symptoms, erectile function, and anxiety after early
reports in the field [26]. The authors looked at TRUS-
guided biopsy only and considered the relationship of
these outcomes with factors such as analgesic approaches
and type of approach to TRUS-guided biopsy. They
found evidence suggesting a transient increase in LUTS,
and a relationship between TRUS-guided biopsy and
erectile dysfunction in the short term. The authors
considered that the impact on erectile dysfunction needed
further research to determine the etiology of this effect.
There was limited justification for choosing to focus on
these outcomes, or why others were omitted.
Efficace et al undertook a systematic review of health-
related quality of life measurements performed in RCTs
relating to prostate carcinoma treatments [29]. The authors
found a range of health-related quality of life assessments;
however, some studies had methodological limitations that7
mpMRI and MRI-Guided Biopsy
could have affected the measurement of health-related
quality of life. The same authors assessed the methodo-
logical quality of patient-reported outcomes in RCTs with
prostate cancer patients in 2014 [30]. The quality of
patient-reported outcomes improved over time, and
approximately 20% of the assessed patient-reported out-
comes were deemed to collate sufficient detail to inform
clinical practice and health policy. These two systematic
reviews focused only on studies of conventional prostate
cancer treatments, excluding any other interventions such
as diagnostic testing or alternative therapies.
There is growing recognition of the importance of
PCOs for diagnostic tests within radiology, especially in
the United States, after the establishment of the PCORI
[31]. There have been methodological challenges in
identifying and measuring PCOs relating to diagnostic
tests that are still being overcome. Many of the direct
effects on patients from undergoing an imaging test are
short term in nature, and not easily captured with
existing measures used in research [32]. The relationship
between these short-term effects and the ultimate patient
outcomemay be tenuous, because diagnostic testingmakes
up just one element in a patient’s illness journey [33].
This review found very little evidence of patient
involvement in identifying outcomes to measure in
studies of prostate cancer diagnostic tests. This finding is
consistent with Mathers et al, who showed that, up until
2006, there was minimal patient engagement to deter-
mine the important patient outcomes for radiology
research [34]. A recent study of outcomes in primary care
for imaging tests interviewed patients who had undergone
x-ray, CT scan, MRI, or ultrasound in the previous 12
months. The four key themes for outcomes that were
identified from patients were knowledge gained from
the test, test contribution to overall health care journey,
physical experiences during the test, and impacts of the
testing process on emotions [35]. Studies in this
systematic review considered only the latter two patient
priorities, but omitted the knowledge gained or the
impact of MRI- or TRUS-guided biopsy on the overall
patient journey.
Strengths and Limitations
This study followed a systematic and comprehensive
methodological approach to understand which PCOs
have been measured in studies of diagnostic tests for
prostate cancer. Published high-quality search strategies
were adapted for the purposes of this study. The search
strategy and definition used for PCOs were deliberately
broad to identify as many relevant studies as possible to8
obtain a clear picture of all current research. Some recent
studies comparing mpMRI and MRI-guided biopsy to
TRUS-guided biopsy were obtained, allowing tentative
conclusions to be drawn between the two diagnostic tests
regarding their comparative effectiveness.
However, this systematic review has some important
limitations affecting the generalizability of the results.
PCO measures have not yet been clearly defined, and
designing a systematic search strategy to capture all
studies measuring PCOs was problematic. It is possible
some studies that could have been included were missed
despite our thorough search methodology. The included
studies varied widely in a number of areas, making meta-
analysis between PCOs for mpMRI or MRI-guided bi-
opsy and TRUS-guided biopsy impossible. Most studies
included in the study had at least some risk of bias based
on the quality assessment, and there were few data re-
ported on PCOs other than physical outcomes of un-
dergoing testing.Implications for Policy and Practice
Within the limited evidence currently available, there is
some indication that mpMRI and MRI-guided biopsy
may perform better than TRUS-guided biopsy in terms
of PCOs. TRUS-guided biopsy is the current standard
diagnostic test for prostate cancer, despite its known
limitations [1]. Following on from the PROMIS [16] and
PRECISION [5] trials showing the higher diagnostic
accuracy of mpMRI and MRI-guided biopsy for pros-
tate cancer, the National Institute for Health and Care
Excellence in the UK has recently updated guidelines for
prostate cancer to include a recommendation for pre-
biopsy mpMRI in all patients with possible prostate
cancer [36]. MRI-based diagnostic pathways for prostate
cancer need further investigation to determine the best
design and the economic impacts of these pathways.
Integration of PCOs into this research would provide
more robust evidence to determine whether mpMRI
and MRI-guided biopsy truly do outperform TRUS-
guided biopsy in key domains other than diagnostic
accuracy.TAKE-HOME POINTS- Studies of mpMRI and MRI-guided biopsy for
prostate cancer have mostly measured physical
PCOs, with very limited evidence about the
emotional, cognitive, behavioral, and social effects
of testing.Journal of the American College of Radiology
Volume - n Number - n Month 2019
- Some evidence suggests mpMRI and MRI biopsy
are associated with fewer adverse PCOs compared
with TRUS biopsy.
- There is no evidence of patient engagement or
involvement in the selection of PCOs for studies of
mpMRI and MRI biopsy for possible prostate
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